Page 60 - Puneet Wadhwa

Use rallies to selectively exit consumption-driven stocks, say analysts

The run up in stock prices, analysts say, could be a short-term phenomenon and the up move could get sold into as employees grapple with salary cuts and job losses in the quarters ahead

Credit cards, Gold ETFs: How India spent and saved during Covid-19 lockdown

Despite the government's efforts to stem the economic fallout of the pandemic, the fall in income levels triggered a fall in consumption/spending

We're in the sell on a rise camp due to weak growth outlook: S Mukherjee

Companies have started talking about a revival, but that is inevitable after a hard lockdown, he says

Global equity markets are likely to continue their up move: Chris Wood

Most analysts agree that the road ahead for the markets will depend on how the government and other policymakers - in India and other countries - adopt measures to combat this crisis.

A fresh round of selling cannot be ruled out: Harshad Patil, Tata AIA Life

The economy, for a large part of the quarter, was under lockdown, and hence the performance of companies would be muted.

Opportunity in crisis: 5 sectors that may gain from coronavirus pandemic

As India moves to open up the country, investors look at sectors that have been resilient. Puneet Wadhwa charts sectors that are expected to do well in the next few months

FPIs may not rush back to India; holding in Nifty50 companies at 23-qtr low

Of the total 50 companies from the Nifty index, FPIs has reduced their holdings in 45 companies during the recently concluded quarter

Second wave of Covid-19 biggest tail risk for markets: BofA Securities

Despite the sharp recovery seen since March lows, 68 per cent of the fund managers surveyed believe that equities are in a bear market rally.

Nifty PSU Bank index hits lowest level in 15 years; SBI at 4-year low

In past one month, the Nifty PSU Bank index underperformed the market by falling 20 per cent, as compared to 3.7 per cent decline in the Nifty 50 index.

Indian economy to contract 5-7% in FY21: Bernstein, Goldman Sachs

Analysts say the Rs 20-trn stimulus package by govt a lost opportunity

Economic package a lost opportunity; FY21 GDP to contract 7%: Bernstein

The overall plan, in their view, was a general economic agenda and lacked substantive decisions to support consumption, promote manufacturing.

Rakesh Jhunjhunwala cuts stake in Titan, Lupin, Escorts in March quarter

Currently, Rakesh Jhunjhunwala and his family's net worth in listed companies stands at Rs 8,517 crore, compared to Rs 8,388 crore as on March 31, 2020.

RIL fixes May 14 as record date for rights issue. Should you subscribe?

Most brokerages expect the company to do well over the coming quarters and peg the target price for the stock higher than its current market price. Subscribing to the issue makes sense, they say

Foreign investors have been cautious about emerging markets: Raychaudhuri

Over the next year, we would expect Sensex and Nifty returns to be in line with their earnings growth

Nomura predicts Indian GDP to contract by 5.2% in FY21, more rate cuts

Analysts at Goldman Sachs expect the Indian economy to contract 0.4 per cent in FY21 versus consensus median 2.7 per cent

Tech-related firms in focus; PPFAS adds Microsoft to portfolio in April

Microsoft is one of the leaders in the cloud computing segment segment, besides Alphabet (Google) and Amazon, making the stock attractive

Stock market eyeing economy reopening, not virus-related data: Chris Wood

As regards the United States (US), Wood expects a gradual opening up in May

India's jewellery demand dips 41% to 11-year low in March quarter: WGC

Global holdings of physically-backed gold ETFs and similar products jumped by 298 tonnes during the March quarter - the highest quarterly inflows for four years

Markets at inflexion point; analysts bullish on consumer, telecom, pharma

The recovery seen in the markets from their March 2020 lows has been quite sharp, with the S&P BSE Sensex and the Nifty50 indices gaining 27.61 per cent and 27.18 per cent, respectively since then

Pharma index set to post its biggest monthly gain in 21 years amid Covid-19

Analysts, however, do caution against the rich valuation the pharma index and the stocks are trading at